Table of Contents
TORONTO — Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced the launch of PrTeva-Fingolimod 0.5 mg capsules, a Health Canada approved, bioequivalent generic version of PrGilenya (fingolimod hydrochloride) in Canada.
PrTeva-Fingolimod (fingolimod hydrochloride) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of physical disability. PrTeva-Fingolimod is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis.
“MS is known as ‘Canada’s disease’ as our country has the highest prevalence in the world, with over 77,000 Canadians currently living with this chronic neurological condition” said Christine Poulin, senior vice President and general manager, Teva Canada. “With the launch of PrTeva-Fingolimod, we are pleased to offer patients a cost-effective, bioequivalent treatment option to PrGilenya and, through the Teva-Fingolimod Patient Care ProgramSM, individualized support and a seamless transition process from brand to generic.”
Teva-Fingolimod Patient Care Program
The Teva-Fingolimod Patient Care Program is designed to support the patient journey for those taking PrTeva-Fingolimod. It will support patients who are moving from the brand (PrGilenya®) medication to Teva Canada’s bioequivalent generic version (PrTeva-Fingolimod) and new patients who are starting fingolimod hydrochloride treatment for the first time.
